OKYO Pharma (OKYO) grants 3,500 shares to chief development officer
Rhea-AI Filing Summary
JACOB GARY S reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd reported that Chief Development Officer Gary S Jacob received a grant of 3,500 shares of common stock on July 21, 2026, at $1.40 per share. After this non-derivative grant, he directly owns 112,420 common shares. The award was not made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,500 shares
Net Buy
1 txn
Insider
JACOB GARY S
Role
CHIEF DEVELOPMENT OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | COMMON STOCK | 3,500 | $1.40 | $5K |
Holdings After Transaction:
COMMON STOCK — 112,420 shares (Direct)
Key Figures
Shares granted: 3,500 shares
Grant price: $1.40 per share
Shares owned after grant: 112,420 shares
3 metrics
Shares granted
3,500 shares
Non-derivative grant on July 21, 2026 to Chief Development Officer Gary S Jacob
Grant price
$1.40 per share
Per-share value for the 3,500-share common stock grant
Shares owned after grant
112,420 shares
Direct common stock holdings of Gary S Jacob following the reported transaction
Key Terms
Grant, award, or other acquisition, non-derivative, direct ownership
3 terms
Grant, award, or other acquisition regulatory
"transaction_code_description: Grant, award, or other acquisition"
non-derivative financial
"transaction_type is noted as non-derivative for the common stock grant"
direct ownership financial
"ownership_type is reported as direct ownership, coded as D"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Gary S Jacob report for OKYO on this Form 4?
Gary S Jacob reported a grant of 3,500 OKYO Pharma common shares on July 21, 2026. The filing classifies it as a non-derivative grant, award, or other acquisition of common stock rather than an open-market purchase or sale.
What are Gary S Jacob’s OKYO (OKYO) holdings after this grant?
Following the reported grant, Gary S Jacob directly holds 112,420 shares of OKYO Pharma common stock. This total reflects his direct ownership immediately after the July 21, 2026 non-derivative award transaction.
Is Gary S Jacob’s ownership in OKYO (OKYO) direct or indirect?
The filing classifies his position as direct ownership, coded as “D” in the ownership fields. After the July 21, 2026 grant, he directly owns 112,420 OKYO Pharma common shares with no indirect ownership entity noted in this report.